Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
Hoffmann-La Roche
Hoffmann-La Roche
Pfizer
Genmab
Allist Pharmaceuticals, Inc.
Janssen Research & Development, LLC
Janssen Research & Development, LLC
MedImmune LLC
M.D. Anderson Cancer Center
Jonsson Comprehensive Cancer Center
M.D. Anderson Cancer Center
Monte Rosa Therapeutics, Inc
Takeda
AstraZeneca
Providence Health & Services
Novartis
EMD Serono
Washington University School of Medicine
Amgen
University of California, Davis
Dizal Pharmaceuticals
H. Lee Moffitt Cancer Center and Research Institute
University of Nebraska
Washington University School of Medicine
M.D. Anderson Cancer Center
University of Colorado, Denver
Indaptus Therapeutics, Inc
Eli Lilly and Company
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Icahn School of Medicine at Mount Sinai
BicycleTx Limited
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Roswell Park Cancer Institute
University of Pittsburgh
Eli Lilly and Company
Immunitas Therapeutics
Deciphera Pharmaceuticals, LLC
M.D. Anderson Cancer Center
Sichuan Baili Pharmaceutical Co., Ltd.
National Cancer Institute (NCI)
BioInvent International AB
Vyriad, Inc.
Proton Collaborative Group
Immuneering Corporation
TCR2 Therapeutics
TCR2 Therapeutics
Cancer Research UK
Affini-T Therapeutics, Inc.
Jonsson Comprehensive Cancer Center